Assembly and Operation of an Acoustofluidic Device for Enhanced Delivery of Molecular Compounds to Cells
January 21st, 2021
2.8K views
This protocol describes the assembly and operation of a low-cost acoustofluidic device for rapid molecular delivery to cells via sonoporation induced by ultrasound contrast agents.
Overview
This protocol describes the assembly and operation of an acoustofluidic system that can efficiently deliver biomolecules for various research and cell-based therapeutic applications. The system allows rapid delivery of biomolecules to cells while maintaining their viability.
Key Study Components
Area of Science
- Acoustofluidics
- Cell-based therapies
- Biomolecule delivery
Background
- Acoustofluidic devices utilize ultrasound for molecular delivery.
- Sonoporation is a technique that enhances cell permeability.
- This method can be applied in cancer treatment and other therapeutic areas.
- Maintaining cell viability during delivery is crucial for therapeutic success.
Purpose of Study
- To develop a low-cost acoustofluidic device.
- To facilitate rapid and efficient delivery of biomolecules to cells.
- To explore applications in cell-based therapies.
Methods Used
- Mixing PDMS base and curing agent to create a mold.
- Using a desiccator to remove air bubbles from the PDMS solution.
- Pouring the PDMS solution over a photoresist coated wafer.
- Assembling the acoustofluidic device for operation.
Main Results
- The device successfully delivers biomolecules to cells.
- Cell viability is maintained during the delivery process.
- The system shows potential for various therapeutic applications.
- Rapid delivery enhances the effectiveness of cell transformation.
Conclusions
- The acoustofluidic device is a promising tool for molecular delivery.
- It can be adapted for different research and therapeutic needs.
- Future studies may explore additional applications in medicine.
Frequently Asked Questions
What is sonoporation?
Sonoporation is a technique that uses ultrasound to increase cell membrane permeability, allowing for the delivery of biomolecules.
How does the acoustofluidic device work?
The device uses ultrasound contrast agents to induce sonoporation, facilitating the rapid delivery of biomolecules to cells.
What materials are used in the device assembly?
The main materials include PDMS base and curing agent for creating the device mold.
What are the advantages of this delivery method?
It allows for rapid delivery while maintaining cell viability, which is crucial for therapeutic applications.
Can this device be used for cancer treatment?
Yes, the device has potential applications in cancer treatment by facilitating the delivery of therapeutic biomolecules.
Executive Industry Relevance
This acoustofluidic platform addresses key bottlenecks in intracellular delivery for cell-based therapeutics by enabling consistent, high-throughput sonoporation under controlled ultrasound exposure. By integrating microfluidics with ultrasound contrast agents, the system reduces variability and improves scalability compared to bulk treatment approaches, supporting reproducible biomolecule delivery in research and manufacturing settings. Enhanced delivery of compounds such as fluorescein and trehalose to human T cells and lung carcinoma cells demonstrates applicability across cell types relevant to immunotherapy and oncology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional interrogation of molecular mechanisms by delivering biomolecules to alter cellular function in human T cells and A549 lung carcinoma cells.
- Operational Value: Provides a reproducible platform for testing compound effects on cell viability and intracellular uptake, supporting target de-risking in early discovery.
Screening & Assay Development
- Scientific Value: Generates quantitative fluorescence readouts (e.g., five-fold increase in fluorescein intensity) to assess delivery efficiency across compound libraries.
- Operational Value: Standardizes ultrasound exposure and flow conditions via syringe or peristaltic pump integration, reducing well-to-well variability in screening assays.
Translational & Preclinical Research
- Scientific Value: Supports preclinical evaluation of biomolecule delivery in clinically relevant cell lines, including primary human T cells and lung cancer models.
- Operational Value: Maintains cell viability above 80% post-treatment, enabling downstream functional assays and phenotypic screening without significant cytotoxicity confounders.
Pipeline & Workflow Integration
The system fits within the discovery-to-preclinical continuum by enabling standardized intracellular delivery for hypothesis testing, compound screening, and mechanistic validation in immune and cancer cell models.
- Discovery Biology: Facilitates rapid delivery of nucleic acids, proteins, or small molecules to probe gene function and signaling pathways in primary and immortalized cell lines.
- Screening: Delivers consistent sonoporation events under controlled flow, improving assay reliability for compound library evaluation.
- Analytics: Enables quantitative assessment of intracellular delivery via fluorescence intensity or other molecular readouts linked to therapeutic efficacy.
- Translational Research: Bridges discovery and preclinical work by demonstrating delivery in human-derived cells used in immunotherapy and oncology pipelines.
- Enterprise Reuse: Designed for adaptation across cell types and biomolecules, supporting reuse in multiple projects without revalidation of core fluidic-ultrasound integration.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence in target validation by enabling controlled, repeatable intracellular delivery of biomolecules.
- Operational Value: Increases throughput and reduces exposure variability compared to bulk sonoporation, improving process consistency in GMP-adjacent workflows.
- Strategic Value: Supports faster go/no-go decisions by providing early, quantitative data on biomolecule delivery efficiency and cellular impact.
- Portfolio Impact: Enables risk-adjusted prioritization of candidates based on delivery efficacy in disease-relevant human cell models.
Implementation Considerations
- Requires expertise in microfluidic device fabrication, including PDMS molding, oxygen plasma bonding, and precision fluidic assembly.
- Depends on access to ultrasound transducers, microcontrollers, and signal generation software for 8 MHz excitation.
- Necessitates standardization of contrast agent preparation (cationic lipid formulation and decafluorobutane gas loading) for reproducible sonoporation.
- Involves optimization of flow rates (e.g., 50 mL/hr via syringe pump) and ultrasound parameters across different cell types and biomolecules.
- Limited by the need for cationic microbubbles; delivery efficiency is significantly reduced without ultrasound contrast agents in solution.
Biopharma FAQs
Why is ultrasound contrast agent critical for delivery?
Intracellular delivery of biomolecules is limited without cationic microbubbles in solution, as contrast agent-mediated cavitation is required to induce sonoporation and transient pore formation in cell membranes.
How does flow rate affect sonoporation consistency?
Setting the syringe pump to 200 mL/hr pushes contrast agent through the device at 50 mL/hr, ensuring uniform ultrasound exposure as cells flow through the acoustofluidic channels.
Fluorescence intensity of delivered fluorescein increased five-fold in treated human T cells versus untreated controls, providing a measurable readout of intracellular uptake.
Cell viability remained above 80% after acoustofluidic treatment, preserving cellular function for downstream applications in immunotherapy and cell-based therapeutic manufacturing.
Compared to bulk approaches, the acoustofluidic system increases throughput and reduces variability in ultrasound exposure, leading to more consistent and scalable biomolecule delivery.
